Back to results
US 10,245,308 B2Granted
Combination therapy utilizing P2X7 peptides
AssigneeBiosceptre (Aust) Pty Ltd
InventorsJulian Alexander Barden, Angus Gidley-Baird
Life of this patent
Estimating the term…
Abstract
The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.
Claims9
A method for minimising the progression of cancer in an individual who has received a non-self antibody or antigen-binding fragment thereof for treatment of the cancer, the method including the step of:
- forming an immune response to a P2X7 receptor in an individual who has received a non self antibody or antigen binding fragment thereof for treatment of the cancer by administering to the individual a P2X7 receptor fragment;
- wherein the fragment of the P2X7 receptor has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3 (KYYKENNVEKRTLIKVF), SEQ ID NO:
- 4 (GHNYTTRNILPGAGAKYYKENNVEK) and SEQ ID NO:
- 5 (GHNYTTRNILPGAGAKYYKENNVEKC);
- wherein cancer in the individual has been reduced in size, mass or other physical measure by the administration of the non self antibody or antigen binding fragment thereof;
- wherein the P2X7 receptor fragment is capable of inducing an antibody response in the individual,
- thereby minimising the progression of cancer in the individual.
5 more elements
A process for forming a humoral immune response to cancer-associated P2X7 receptors in an individual who has received an anti-cancer antigen antibody for therapy of cancer, including the steps of:
- forming an immune response in the individual by administering to the individual P2X7 receptor fragment wherein the fragment of the P2X7 receptor has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3 (KYYKENNVEKRTLIKVF), SEQ ID NO:
- 4 (GHNYTTRNILPGAGAKYYKENNVEK) and SEQ ID NO:
- 5 (GHNYTTRNILPGAGAKYYKENNVEKC);
- wherein the P2X7 fragment is capable of inducing an antibody response in the individual,
- wherein the immune response is formed in the individual at a time where anti-cancer antigen antibody administered for treatment of cancer is at a level or concentration that is substantially undetectable in the individual;
- and/or
- the humoral immune response to cancer-associated P2X7 receptors is formed according to an immunisation schedule whereby the amount of antibody formed in the individual to cancer-associated P2X7 receptor is about 0.1 to 25 mg/kg individual.
5 more elements
Dependencies are inferred from the claim text.